Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Rain Oncology Inc. (RAIN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/13/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/17/2023 |
SC 13D/A
| BIOTECHNOLOGY VALUE FUND L P reports a 12.8% stake in Rain Oncology Inc. |
| 08/11/2023 |
4
| Vellanki Avanish (Chairman and CEO) has filed a Form 4 on Rain Oncology Inc.|
Txns:
| Granted 266,500 options to buy
@ $1.21, valued at
$322.5k
Granted 133,250 options to buy
@ $1.21, valued at
$161.2k
|
|
| 08/11/2023 |
4
| Doebele Robert (See Remarks) has filed a Form 4 on Rain Oncology Inc.|
Txns:
| Granted 99,400 options to buy
@ $1.21, valued at
$120.3k
Granted 49,700 options to buy
@ $1.21, valued at
$60.1k
|
|
| 08/11/2023 |
4
| BERGER FRANKLIN M (Director) has filed a Form 4 on Rain Oncology Inc.|
Txns:
| Granted 35,000 options to buy
@ $1.21, valued at
$42.4k
|
|
| 08/11/2023 |
4
| Radovich Peter (Director) has filed a Form 4 on Rain Oncology Inc.|
Txns:
| Granted 35,000 options to buy
@ $1.21, valued at
$42.4k
|
|
| 08/11/2023 |
4
| Nguyen Tran (Director) has filed a Form 4 on Rain Oncology Inc.|
Txns:
| Granted 35,000 options to buy
@ $1.21, valued at
$42.4k
|
|
| 08/11/2023 |
4
| Wolff Stefani (Director) has filed a Form 4 on Rain Oncology Inc.|
Txns:
| Granted 35,000 options to buy
@ $1.21, valued at
$42.4k
|
|
| 08/11/2023 |
4
| Hrustanovic Gorjan (Director) has filed a Form 4 on Rain Oncology Inc.|
Txns:
| Granted 35,000 options to buy
@ $1.21, valued at
$42.4k
|
|
| 08/11/2023 |
4
| Davis Aaron I. (Director) has filed a Form 4 on Rain Oncology Inc.|
Txns:
| Granted 35,000 options to buy
@ $1.21, valued at
$42.4k
|
|
| 08/11/2023 |
4
| Atkisson Erik (General Counsel and CCO) has filed a Form 4 on Rain Oncology Inc.|
Txns:
| Granted 60,251 options to buy
@ $1.21, valued at
$72.9k
|
|
| 08/11/2023 |
4
| Bruce Josephine (Principal Fin. & Acc. Officer) has filed a Form 4 on Rain Oncology Inc.|
Txns:
| Granted 10,800 options to buy
@ $1.21, valued at
$13.1k
|
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 06/09/2023 |
3
| Bruce Josephine (Principal Fin. & Acc. Officer) has filed a Form 3 on Rain Oncology Inc. |
| 06/01/2023 |
4
| TANG KEVIN C (10% Owner) has filed a Form 4 on Rain Oncology Inc.|
Txns:
| Bought 347,932 shares
@ $1.05, valued at
$365.3k
Bought 200,000 shares
@ $1, valued at
$200k
Bought 32,890 shares
@ $1.06, valued at
$34.9k
Bought 2,016 shares
@ $1.08, valued at
$2.2k
Bought 5,930 shares
@ $1.06, valued at
$6.3k
Bought 161,180 shares
@ $1.08, valued at
$174.1k
Bought 5,000 shares
@ $1.1, valued at
$5.5k
Bought 92,984 shares
@ $1.09, valued at
$101.4k
Bought 240,341 shares
@ $1.12, valued at
$269.2k
|
|
| 06/01/2023 |
3
| TANG KEVIN C (10% Owner) has filed a Form 3 on Rain Oncology Inc. |
| 06/01/2023 |
SC 13D
| TANG CAPITAL PARTNERS LP reports a 14.1% stake in Rain Oncology Inc. |
| 05/24/2023 |
4
| Boxer Capital, LLC (Director) has filed a Form 4 on Rain Oncology Inc.|
Txns:
| Sold 995,000 shares
@ $1.25, valued at
$1.2M
|
|
| 05/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"RAIN ONCOLOGY INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31, 2023 2022 Operating expenses: Research and development $ 16,677 $ 13,555 General and administrative 5,066 3,895 Total operating expenses 21,743 17,450 Loss from operations Other income: Interest income 1,259 56 Total other income 1,259 56 Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average shares used in computing net loss per share, basic and diluted 36,339,851 26,511,743 SUMMARY CONDENSED CONSOLIDATED BALANCE SHEET DATA" |
|
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
SC 13G/A
| Flynn James E reports a 0% stake in Rain Oncology Inc. |
| 04/19/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/19/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/19/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/09/2023 |
8-K
| Quarterly results|
Docs:
|
"Three Months Ended December 31, Twelve Months Ended December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 19,078 $ 14,672 $ 61,400 $ 40,773 General and administrative 4,479 3,405 15,736 10,739 Total operating expenses 23,557 18,077 77,136 51,512 Loss from operations Other income: Interest and other income 882 94 1,415 120 Total other income 882 94 1,415 120 Net loss before income tax expense Income tax expense Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average shares used to compute net loss per share, basic and diluted 32,288,083 26,470,600 27,985,446 19,405,833 SUMMARY CONSOLIDATED BALANCE SHEET DATA" |
|
| 02/14/2023 |
SC 13G
| Samsara BioCapital, L.P. reports a 9.1% stake in Rain Oncology Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Global Healthcare Master Fund, LP reports a 10% stake in Rain Oncology Inc. |
| 02/14/2023 |
SC 13G/A
| PERCEPTIVE ADVISORS LLC reports a 9.3% stake in Rain Oncology Inc. |
| 02/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 01/30/2023 |
SC 13G
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 8.1% stake in Rain Oncology, Inc. |
|
|
|